Intellectual Property Applications in Science & Engineering

Intellectual property (IP) is pervasive in modern society, especially in the sciences and engineering. The U.S. Department of Commerce recently found that IP-intensive industries added $5.06 trillion, or 34.8%, of value to the U.S. gross domestic product and 40 million jobs in 20121. IP rights allow inventers, authors, and owners to exclude others from unauthorized use or reproduction of IP, making them very valuable assets, especially in the pharmaceutical, energy production, material production, nanotechnology, and biotechnology industries. As professionals, science and engineering students will encounter and create IP in the form of patents, trademarks, copyrights, and trade secrets. However, IP is generally overlooked in engineering and science curriculums and professional development and without a working understanding of IP valuable inventions and creative works may be lost. This talk will discuss the application, protection, and ownership of patents, copyrights, trademarks, and trade secrets that science and engineering professionals may encounter, strategies in handling them, and approaches to commercialization and avoiding infringement. 1. Econ. & Statistics Admin. & U.S. Patent & trademark Office, Intellectual Property and the U.S. Economy: Industries in Focus (2012

Exotic herbivores and fire energy drive standing herbaceous biomass but do not alter compositional patterns in a semiarid savanna ecosystem

Questions: Fire regime alterations are pushing open ecosystems worldwide past tipping points where alternative steady states characterized by woody dominance prevail. This reduces the frequency and intensity of surface fires, further limiting their effectiveness for controlling cover of woody plants. In addition, grazing pressure (exotic or native grazers) can reinforce woody encroachment by potentially reducing fine-fuel loads. We investigated the effects of different fire energies on the herbaceous plant community, together with mammalian wildlife herbivory (exotic and native combined) exclusion, to inform best management practices. Location: Texas semi-arid savanna, southern Great Plains, USA. Methods: We conducted an experiment in which we manipulated fire intensity and herbivore access to herbaceous biomass in a split-plot design. We altered fire energy via fuel addition rather than applying fire under different environmental conditions to control for differences in standing biomass and composition attributable to differential plant physiological status and fire season. Results: High-energy fire did not reduce herbaceous biomass or alter plant community composition, although it did increase among-plot variability in composition and forb biomass relative to low-energy fire and non-burned controls. Grazing pressure from native and non-native mammalian herbivores reduced above-ground herbaceous biomass regardless of fire treatments, but did not alter community composition. Conclusions: Managers seeking to apply high-intensity prescribed fire to reduce woody encroachment will not negatively impact herbaceous plant productivity or alter community composition. However, they should be cognizant that repeated fires necessary for greatly reducing woody plants in heavily invaded areas might be difficult to accomplish due to fine-fuel reduction from wild herbivores. High fencing to restrict access by wildlife herbivores or culling might be necessary to build fuels sufficient to conduct high-intensity burns for woody-plant reductio

A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes:the MET-REMODEL trial

Aim We tested the hypothesis that metformin may regress left ventricular hypertrophy (LVH) in patients who have coronary artery disease (CAD), with insulin resistance (IR) and/or pre-diabetes. Methods and results We randomly assigned 68 patients (mean age 65 ± 8 years) without diabetes who have CAD with IR and/or pre-diabetes to receive either metformin XL (2000 mg daily dose) or placebo for 12 months. Primary endpoint was change in left ventricular mass indexed to height1.7 (LVMI), assessed by magnetic resonance imaging. In the modified intention-to-treat analysis (n = 63), metformin treatment significantly reduced LVMI compared with placebo group (absolute mean difference −1.37 (95% confidence interval: −2.63 to −0.12, P = 0.033). Metformin also significantly reduced other secondary study endpoints such as: LVM (P = 0.032), body weight (P = 0.001), subcutaneous adipose tissue (P = 0.024), office systolic blood pressure (BP, P = 0.022) and concentration of thiobarbituric acid reactive substances, a biomarker for oxidative stress (P = 0.04). The glycated haemoglobin A1C concentration and fasting IR index did not differ between study groups at the end of the study. Conclusion Metformin treatment significantly reduced LVMI, LVM, office systolic BP, body weight, and oxidative stress. Although LVH is a good surrogate marker of cardiovascular (CV) outcome, conclusive evidence for the cardio-protective role of metformin is required from large CV outcomes trials

Miscellaneous Rheumatic Diseases [73-83]: 73. Is There a Delay in Specialist Referral of Hot Swollen Joint?

Background: Patients with acute, hot, swollen joints commonly present to general practitioners, emergency departments and/or acute admitting teams rather than directly to rheumatology. It is imperative to consider septic arthritis in the differential diagnosis of these patients. The British Society of Rheumatology (BSR) has produced guidelines for the management of this condition, which include recommendations for early specialist referral and joint aspiration of all patients with suspected septic arthritis. We examined whether the initial management of patients with acute hot swollen joint(s) at University College London Hospital (UCLH) follows BSR guidelines. Methods: For the period Feb to Nov 2009, appropriate patients were identified by searching the UCLH database using the diagnostic terms, "pyogenic arthritis”, "septic arthritis” and "gout”; and from all joint aspirate requests sent to microbiology. Medical notes were obtained and any patients who had elective arthroscopies or chronic (> 6 weeks) symptoms were excluded. Data were collected on the time taken from the onset of symptoms to specialist (orthopaedic/rheumatology) referral and joint aspiration, collection of blood cultures and antibiotic treatment with or without microbiology advice. Results: Twenty patients were identified with hot swollen (18 monoarticular, 3 prosthetic) joint(s) of < 2 weeks duration. Of whom, 3/20 (15%) were admitted directly to rheumatology, 7/20 (35%) to the acute admissions unit, 3/20 (15%) to orthopaedic, 4/20 (20%) to a medical team and 1/20 (5%) to general surgery. In 19 (95%) cases, specialist (rheumatology/orthopaedic) advice was sought. Of 14 cases not seen directly by specialists 9 (64%) were referred at 24-48 h and 5 (36%) at 48-192 h. All 20 patients had joint aspiration. In 9/20 (45%) of cases, joint aspiration was performed in less than 6 h, 3/20 (15%) cases at 6-24h and 6/20 (30%) cases at 24-192 h and was not recorded in two patients. Of these, crystals were identified in two and one was culture positive. Blood cultures were received for only 6/20 (30%) of cases and only clearly documented to have been taken prior to antibiotic therapy and none were positive. Of 14/20 (70%) started on antibiotic treatment empirically, only 6 (42%) were preceded by joint aspiration. In the 6 patients not treated with antibiotics due to low index of suspicion of septic arthritis, synovial fluid and blood cultures were negative. Microbiology advice was sought in 10/20 (50%) of cases by the admitting teams but the timing of this advice is unclear. Conclusions: Despite the provision of 24 h rheumatology and orthopaedic cover at UCLH, we found a significant delay in acute medical firms seeking specialist advice on the management of patients with acute, hot swollen joints with subsequent deviation from BSR guidelines. Consequently, we plan to increase awareness of these guidelines amongst medical firms at UCLH. Disclosure statement: All authors have declared no conflicts of interes

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

Stimuli-responsive liposome-nanoparticle assemblies

Introduction: Nanoscale assemblies are needed that achieve multiple therapeutic objectives, including cellular targeting, imaging, diagnostics and drug delivery. These must exhibit high stability, bioavailability and biocompatibility, while maintaining or enhancing the inherent activity of the therapeutic cargo. Liposome-nanoparticle assemblies (LNAs) combine the demonstrated potential of liposome-based therapies, with functional nanoparticles. Specifically, LNAs can be used to concentrate and shield the nanoparticles and, in turn, stimuli-responsive nanoparticles that respond to external fields can be used to control liposomal release. The ability to design LNAs via nanoparticle encapsulation, decoration or bilayer-embedment offers a range of configurations with different structures and functions. Areas covered: This paper reviews the current state of research and understanding of the design, characterization and performance of LNAs. A brief overview is provided on liposomes and nanoparticles for therapeutic applications, followed by a discussion of the opportunities and challenges associated with combining the two in a single assembly to achieve controlled release via light or radiofrequency stimuli. Expert opinion: LNAs offer a unique opportunity to combine the therapeutic properties of liposomes and nanoparticles. Liposomes act to concentrate small nanoparticles and shield nanoparticles from the immune system, while the nanoparticle can be used to initiate and control drug release when exposed to external stimuli. These properties provide a platform to achieve nanoparticle-controlled liposomal release. LNA design and application are still in infancy. Research concentrating on the relationships among LNA structure, function and performance is essential for the future clinical use of LNAs. © 2011 Informa UK, Ltd

Bilayer heating in magnetite nanoparticle-liposome dispersions via fluorescence anisotropy

Temperature measurements have been made within magnetite (Fe3O4) nanoparticle-liposome dispersions subjected to electromagnetic field at radiofrequency (RF) heating based on the fluorescence anisotropy of diphenylhexatriene (DPH) embedded within the bilayer. Incorporating cholesterol within dipalmitoylphosphatidylcholine (DPPC) bilayers broadened the anisotropy window associated with lipid melting. Cryogenic transmission electron microscopy showed that the dispersions contained magnetoliposomes with nanoparticle aggregates at both low and high encapsulation densities. RF heating results demonstrated the ability to measure the temperature of the ML bilayer with on/off RF cycles using DPH anisotropy. These measurements reflected the temperature of the bulk aqueous phase, which is consistent with previous work showing rapid heat dissipation from a nanoparticle surface during RF heating and a negligible difference between surface and bulk temperature. © 2011 Elsevier Inc